In This Section

Research Funding Impact

Since 1993, the AACR has awarded more than $480 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.

Search/Filter
Loading...
Dr. Carsten Hagemann on AACR-Novocure TTFields Research Grant Impact

Dr. Carsten Hagemann on AACR-Novocure TTFields Research Grant Impact

The AACR-Novocure Tumor Treating Fields Research Grants represent a joint effort to promote and support innovative research focused on Tumor Treating Fields (TTFields), which are intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells. 2020 grant recipient Carsten Hagemann, PhD, shares his perspectives on the myriad benefits of the grant.

Ravi Majeti and the Elusive Cells

Ravi Majeti and the Elusive Cells

After undergraduate education at Harvard University, Ravi Majeti earned his MD and PhD at University of California San Francisco. He took an interest in acute myeloid leukemia (AML) in medical school and cared for patients with AML during his residency in internal medicine at Brigham and Women’s Hospital in Boston and Hematology fellowship at Stanford University...

AACR – J&J Lung Cancer Innovative Science Grants: Cutting-Edge Approaches to Cut Down Cancer Risk

AACR – J&J Lung Cancer Innovative Science Grants: Cutting-Edge Approaches to Cut Down Cancer Risk

Lung cancer remains the number one cause of cancer-related death. This persistent dismal prognosis has been largely attributed to late-stage diagnosis, when 5-year survival rates are less than 5%. Although the potential of lung cancer screening to reduce lung cancer-related mortality has been demonstrated, there remains a need for more effective and less invasive early detection methods. The AACR-Johnson & Johnson Lung Cancer Innovative Science Grants are fueling...

AACR Grantee Indicates Novel Mechanism to Enhance Efficacy of Immune Therapies in High Grade Serous Ovarian Cancer

AACR Grantee Indicates Novel Mechanism to Enhance Efficacy of Immune Therapies in High Grade Serous Ovarian Cancer

Despite demonstrated success in many solid tumor types, immune checkpoint blockade (ICB) agents have minimal efficacy in high grade serous ovarian cancer (HGSC). In this study, the authors describe a novel bispecific anti-PD-1/PD-L1 antibody, which showed increased anti-tumor efficacy compared to mono-specific anti-PD-1 or anti-PDL1. The researchers also...

Dr. Channing Der on PanCAN-AACR Grants Impact

Dr. Channing Der on PanCAN-AACR Grants Impact

Dr. Channing Der serves as the Sarah Graham Kenan Professor of Pharmacology at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill. Having received his PhD from the University of California at Irvine, Dr. Der went on to complete his postdoctoral research training at the Dana-Farber Cancer Institute and Harvard Medical School. As a two-time PanCAN-AACR grant recipient...